High-Risk Assessment of Early Breast Cancer IV

  • As with other early breast cancers (eg, hormone-positive or triple-negative), risk for recurrence of a HER2-positive tumor is generally dependent on tumor size, presence of positive axillary lymph nodes, tumor grade, and other histologic and patient factors
  • Before the development of effective anti-HER2 therapies, such as trastuzumab, novel anti-HER2 tyrosine kinase inhibitors (TKIs), or antibody drug conjugates (ADCs) HER2 positivity was associated with poor prognosis
  • The degree of HER2 positivity (ie, IHC 2+/FISH amplified vs IHC 3+) is not correlated with recurrence risk, although it may be associated with greater responsiveness to anti-HER2–targeted therapies
  • Patients with early-stage, HER2-positive tumors with clinically positive lymph nodes are candidates for neoadjuvant systemic treatment with chemotherapy and pertuzumab plus trastuzumab
#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #MountSinaiMedicalCenter #MSMC #Miami #Mexico #BreastCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s